Cellectis leverages its leadership in gene editing through its flagship technology, TALEN ®, which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly available, off-the-shelf therapies.TALEN ® has been successfully used in the clinic to solve key challenges with allogeneic CAR T including protection from …

2011年8月29日 · Cellestis has developed and successfully commercialized the QuantiFERON ® technology, a proprietary approach for early disease detection not possible with other diagnostic methods. Cellestis' QuantiFERON ®-TB Gold (QFT) is a …

关于Cellestis. Cellestis有限公司是一家澳大利亚上市诊断公司，基于QuantiFERON®技术在全球研发和生产肺结核及其他疾病的检测产品。QuantiFERON®-TB Gold试剂能够检测由病人白血细胞受某种特定肺结核蛋白质刺激而导致的蛋白质（γ-干扰素）存在与缺失。

2015年4月20日 · Cellectis S.A. 与 Allogene Therapeutics, Inc. 和 Les Laboratoires Servier 建立了战略联盟；与 Iovance Biotherapeutics, Inc. 建立了研究合作并签署了独家许可协议；与 AstraZeneca Holdings B.V. 以及 AstraZeneca Ireland Limited 建立了联合研究与合作及投资协议。. Cellectis S.A.(CLLS)技术/科技. 基因编辑的真正威力在于能够精确选择编辑 ...

NEW YORK (GenomeWeb News) – Qiagen today said that it has completed the acquisition of all of the ordinary shares of Melbourne, Australia-based Cellestis for A$3.80 (US$4.04) per share. Australian Court Approves Qiagen's Purchase of Cellestis Shares

QIAGEN’s acquisition of Cellestis Ltd. adds a new detection technology – QuantiFERON – to the company’s sample and assay technologies portfolio. QuantiFERON is a “premolecular” technology that allows detection of many diseases far earlier than possible with other methods, including DNA- and RNA-based molecular diagnostics. This

2025年2月27日 · Cellestis developed diagnostic solutions for the detection of latent infections. Its platform QuantiFERON technology is a "pre-molecular" test that is capable of detecting very low viral loads which are otherwise undetectable by regular sequencing methods.

Cellestis是一家涉及医疗诊断和科学研究的公司，并是QuantiFERON技术的开发商兼产品营销商。 QuantiFERON专利技术是一种利用全血技术，就介导免疫淋巴细胞对T细胞的反应进行检测。

Cellestis Limited 简介. Cellestis Limited 是一家于2000年在澳大利亚墨尔本成立的上市生物科技公司，旨在开发和生产 QuantiFERON-TB Gold (QFT) 检测试剂，QFT 是结核病检测和控制方面的一项突破性血液检测方法。

Cellestis Limited是一家生物技术公司，主要在美国，欧洲，澳大利亚和日本开发、生产和销售医疗诊断产品。 它开发和销售用于医疗诊断和科学研究的QuantiFERON技术产品。